|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Pancreatic Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Pancreatic Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Pancreatic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| tipifarnib | |||||
| radiation therapy | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| University of Pennsylvania | |||||
| National Cancer Institute (NCI) | |||||